142 related articles for article (PubMed ID: 37927219)
21. Successful re-challenge with anti-BRAF and anti-MEK in a patient with symptomatic melanoma flare.
Ibrahim T; Routier E; Weill A; Baz M; Robert C
Eur J Cancer; 2017 Sep; 82():25-26. PubMed ID: 28646770
[No Abstract] [Full Text] [Related]
22. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
[TBL] [Abstract][Full Text] [Related]
23. Clinical Development of BRAF plus MEK Inhibitor Combinations.
Subbiah V; Baik C; Kirkwood JM
Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454
[TBL] [Abstract][Full Text] [Related]
24. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.
Samlowski W; Adajar C
BMC Cancer; 2021 Nov; 21(1):1187. PubMed ID: 34743688
[TBL] [Abstract][Full Text] [Related]
25. [Unusual association of BRAF and MEK inhibitors: Clinical response of metastatic melanoma treated with dabrafenib-cobimetinib].
Leenhardt F; Mbatchi L; Evrard A; Cupissol D; Lesage C
Bull Cancer; 2023; 110(7-8):865-868. PubMed ID: 36966054
[TBL] [Abstract][Full Text] [Related]
26. Edoxaban prevented adverse effects including pyrexia and elevation of D-dimer caused by the combination of BRAF and MEK inhibitors in a patient with BRAF-mutant melanoma.
Mukai K; Kamata M; Miyazaki M; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Ishikawa T; Ohnishi T; Tada Y; Tanaka T
J Dermatol; 2021 May; 48(5):707-709. PubMed ID: 33600004
[TBL] [Abstract][Full Text] [Related]
27. Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?
Schummer P; Schilling B; Gesierich A
Am J Clin Dermatol; 2020 Aug; 21(4):493-504. PubMed ID: 32124332
[TBL] [Abstract][Full Text] [Related]
28. Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice.
Augustyn K; Joseph J; Patel AB; Razmandi A; Ali AN; Tawbi HA
Melanoma Res; 2023 Oct; 33(5):406-416. PubMed ID: 37534686
[TBL] [Abstract][Full Text] [Related]
29. Severe colitis in patients with melanoma treated with BRAF/MEK inhibitors.
Carbonnel F; Routier E; Lazure T; Mussini C; Bellanger C; Merklen C; Bejou B; Buisson A; Amiot A; Meyer A; Dong C; Robert C
Aliment Pharmacol Ther; 2023 Apr; 57(7):792-799. PubMed ID: 36578099
[TBL] [Abstract][Full Text] [Related]
30. Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis.
Erkes DA; Cai W; Sanchez IM; Purwin TJ; Rogers C; Field CO; Berger AC; Hartsough EJ; Rodeck U; Alnemri ES; Aplin AE
Cancer Discov; 2020 Feb; 10(2):254-269. PubMed ID: 31796433
[TBL] [Abstract][Full Text] [Related]
31. Use of proton pump inhibitors in people taking BRAF/MEK inhibitors for metastatic melanoma.
Br J Dermatol; 2023 Mar; 188(4):e29. PubMed ID: 36994709
[No Abstract] [Full Text] [Related]
32. A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors.
Awada G; Schwarze JK; Tijtgat J; Fasolino G; Kruse V; Neyns B
Melanoma Res; 2022 Jun; 32(3):183-191. PubMed ID: 35377866
[TBL] [Abstract][Full Text] [Related]
33. Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.
Devji T; Levine O; Neupane B; Beyene J; Xie F
JAMA Oncol; 2017 Mar; 3(3):366-373. PubMed ID: 27787543
[TBL] [Abstract][Full Text] [Related]
34. Histiocytoid Sweet's syndrome during combined therapy with BRAF and MEK inhibitors for metastatic melanoma.
Morgado-Carrasco D; Moreno-Rivera N; Fustà-Novell X; García-Herrera A; Carrera C; Puig S
Melanoma Res; 2018 Jun; 28(3):256-257. PubMed ID: 29683894
[No Abstract] [Full Text] [Related]
35. Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma: the more the better?
Trojaniello C; Vitale MG; Ascierto PA
Curr Opin Oncol; 2021 Mar; 33(2):133-138. PubMed ID: 33399314
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies.
Dulgar O; Kutuk T; Eroglu Z
Am J Clin Dermatol; 2021 Jan; 22(1):1-10. PubMed ID: 33368052
[TBL] [Abstract][Full Text] [Related]
37. A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma
Tarhini AA; Toor K; Chan K; McDermott DF; Mohr P; Larkin J; Hodi FS; Lee CH; Rizzo JI; Johnson H; Moshyk A; Rao S; Kotapati S; Atkins MB
ESMO Open; 2021 Apr; 6(2):100050. PubMed ID: 33556898
[TBL] [Abstract][Full Text] [Related]
38. Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma.
Schmitt AM; Dumas L; Larkin J
Expert Rev Anticancer Ther; 2022 Jan; 22(1):17-25. PubMed ID: 34904502
[TBL] [Abstract][Full Text] [Related]
39. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
Ribas A; Lawrence D; Atkinson V; Agarwal S; Miller WH; Carlino MS; Fisher R; Long GV; Hodi FS; Tsoi J; Grasso CS; Mookerjee B; Zhao Q; Ghori R; Moreno BH; Ibrahim N; Hamid O
Nat Med; 2019 Jun; 25(6):936-940. PubMed ID: 31171879
[TBL] [Abstract][Full Text] [Related]
40. Sequential treatment failures in response to BRAF/MEK and immune checkpoint inhibitors mediated by MAP2K2 and B2M mutations in melanoma.
Richmond CS; Vallatharasu Y; Deviley JA; Vos CR; Parsons BM; Kenny PA
Exp Mol Pathol; 2019 Oct; 110():104260. PubMed ID: 31082388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]